words lines 0 60 0 20 top 50% bottom top 1 0 0 .22 back 1 0 .001 1 .1 1.5 none top bottom center center true 1 none top top center top true 0 200 .001 none
top bottom top center true 1 none top bottom bottom bottom true 1 none

Pipeline

Pipeline for continuous benefit to patients.

We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes first-in-class therapies aimed at providing new solutions and  support where no options currently exist, with a goal to help lift the burden for patients.

TISSUEGENE-C (TG-C)

TG-C is a non-surgical treatment cell-mediated gene therapy for osteoarthritis, which is the most common form of arthritis. A first-in-class cell and gene therapy, TG-C targets knee osteoarthritis through a single intra-articular injection.

Pre-clinical

Phase 1

Phase 2

Phase 3

Regulatory

%
Grade 3 knee osteoarthritis

LEGADA®

LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for the treatment of MF-CTCL in adult patients). Since June 2019, LEDAGA® is commercialized in more than 30 countries including Europe, Canada, Latin America.

Pre-clinical

Phase 1

Phase 2

Phase 3

Regulatory

%
Topical treatment of MF-CTCL

TRUSELTIQ®

TRUSELTIQ® (infigratinib) capsules 25mg/100mg is indicated for the treatment of adults with previously treated, unrespectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

TRUSELTIQ® is a pipeline therapy which has already been approved for 2nd Line with Phase 3 Trials and is currently under investigation as a potential first-line treatment for individuals with Adjuvant Urothelial Cancer in Australia.

Pre-clinical

Phase 1

Phase 2

Phase 3

Regulatory

%
2nd Line Cholangiocarcinoma
%
1st Line Cholangiocarcinoma
%
Adjuvant Urothelial Cancer

Anamorelin

ANAMORELIN is a novel once-daily, orally active ghrelin receptor agonist indicated for the treatment of cancer cachexia in patients suffering from malignant tumors of non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer or colorectal cancer. Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight (especially decreased muscle mass) and anorexia associated with cancer. It has been well documented that cancer cachexia causes a significant impact on patients’ quality of life (QOL) and prognosis.

Pre-clinical

Phase 1

Phase 2

Phase 3

Regulatory

%
Cancer Anorexia-Cachexia in NSCLC patients